Local view for "http://purl.org/linkedpolitics/eu/plenary/2005-10-25-Speech-2-291"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2005-10-25"^^xsd:date2
dcterms:Is Part Of	lp_eu:Patents for biotechnological inventions2
dcterms:Language	"pl"^^xsd:language2
lpv:document identification number	"en.20051025.22.2-291"2
lpv:hasSubsequent	lp_eu:2005-10-25-Speech-2-2922
lpv:speaker	lp:Maciej Marian Giertych2
lpv:spokenAs	chair_of_the_bureau; IND/DEM (2004-07-20--2005-12-14)3 member; AFET (2004-07-21--2007-01-14)3 substitute; Delegation for relations with Japan (2004-11-18--2005-12-14)3 member; Delegation for relations with the United States (2004-09-15--2007-03-13)3 substitute; ENVI (2004-07-21--2005-12-14)3 substitute; DROI (2004-09-14--2005-12-14)3 unknown; Liga Polskich Rodzin (2004-07-20--2009-07-13)3
lpv:translated text	"Mr President, research into the use of stem cells to treat various diseases is currently in vogue. Using cells from embryos is unethical, whereas such considerations are irrelevant when adult stem cells are used. Around 95% of research funding is spent on the former, although no benefits have been derived from them, whereas only 5% of funding is spent on the latter, which offer many advantages. This begs the question of what is really going on here. On 12 May, Professor Scolding, a neurophysiologist from the University of Bristol, gave an extremely interesting talk to Parliament’s Intergroup on Bioethics, during which he explained a great many facets of this issue. Embryonic stem cells are carcinogenic and prone to genetic mutations, and problems can arise due to their being rejected. They do not normally perform repair functions, and hence have to be forced to do so. Furthermore, ethical considerations surround the use of such cells. Adult stem cells taken from bone marrow, on the other hand, are intended to act in a healing capacity, and do not need to be forced to carry out tasks other than those for which they are adapted. No problems are posed in terms of the rejection of such cells, since a patient’s own cells are not carcinogenic and do not cause genetic mutations. What is more, the use of such cells is ethically unproblematic. Professor Scolding is not the only one who knows about all these research findings, and in fact all experts in this field are familiar with them. The question we should therefore be asking is why so much money is spent on research into embryonic stem cells, and so little on research into adult stem cells. The answer is that no opportunities exist for the manufacture of drugs using the latter, since the cells themselves, which are harvested directly from the patient, are the drug. Drug manufacturers would earn nothing in such instances. In the case of embryonic stem cells, however, what counts is the fact that cell lines can be cultivated for various purposes and then sold, and this is why so much money is poured into research in this area. Such are the consequences of patents on cells."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph